Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

C-Peptide Medication-Driven Changes: What Your Labs Mean and How Drugs Shift the Numbers

By
Published Updated Last reviewed
8 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • What C-peptide reflects / One molecule released with each molecule of insulin [1][4]
  • Injected insulin / No C-peptide of its own; suppresses the body's own secretion [1][2]
  • Sulfonylureas / Insulin and C-peptide high together [3][2]
  • Kidney function / Levels 2 to 5 times higher in moderate to severe kidney disease [2]
  • Low glucose / Suppresses insulin and C-peptide [2]
  • Reference range / No single standard; fasting lower limits 0.165 to 0.364 nmol/L [5]
  • Units / 1 nmol/L equals about 3 ng/mL [1][2]

What the test measures

C-peptide is a chain of amino acids the pancreas makes while it makes insulin, and the two enter the bloodstream at the same time in equal amounts [4]. Injected insulin contains no C-peptide, which is what lets the test separate the body's own insulin output from insulin taken as medicine [1][4]. It is used to work up low blood glucose, to guide diabetes treatment and, in some cases, to sort type 1 from type 2 diabetes; it is not used to diagnose diabetes [4]. Units matter: 1 nmol/L equals 1,000 pmol/L, or about 3 ng/mL, so 0.2 nmol/L is about 0.6 ng/mL [1][2].

Injected insulin

During a hypoglycemia work-up, injected insulin produces a pattern of suppressed C-peptide (generally to the lower limit of normal) with high insulin [2][3].

In the DCCT, 303 participants with type 1 diabetes of 1 to 5 years had a stimulated C-peptide of 0.20 to 0.50 pmol/mL after a mixed meal. In these participants, intensive therapy (three or more insulin injections daily or continuous subcutaneous infusion) maintained a higher stimulated C-peptide and reduced the likelihood of becoming a non-responder by 57% (95% CI 39% to 71%) compared with conventional therapy using one or two injections daily [6].

Sulfonylureas

In a documented hypoglycemic episode, high insulin with high C-peptide points either to a sulfonylurea or to an insulinoma, and a screen for circulating oral hypoglycemic agents separates the two [3][2].

What moves the number without a drug

A random C-peptide below 200 pmol/L suggests absolute insulin deficiency only when plasma glucose is above 8 mmol/L (144 mg/dL); low glucose itself can suppress C-peptide [2][1].

C-peptide is cleared by the kidneys, so levels run roughly 1.5 to 3 times higher when eGFR is 30 to 59 and 3 to 5 times higher when it is 15 to 29, and interpretation is unreliable below eGFR 15 [2].

There is no single standard reference range: published fasting lower limits run from 0.165 to 0.364 nmol/L and upper limits from 0.596 to 1.5 nmol/L, and two assay systems differed by as much as 36% [5].

Frequently asked questions

Does injected insulin lower C-peptide?
Injected insulin contains no C-peptide and suppresses the body's own C-peptide toward the lower limit of normal; during a hypoglycemia work-up the expected pattern is suppressed C-peptide with high insulin [2][3].
Do sulfonylureas raise C-peptide?
They raise insulin and C-peptide together. In a documented hypoglycemic episode that pattern points to a sulfonylurea or an insulinoma, and a screen for oral hypoglycemic agents separates the two [3][2].
Can kidney disease raise C-peptide?
Yes. C-peptide is cleared by the kidneys, and levels run roughly 1.5 to 3 times higher when eGFR is 30 to 59 and 3 to 5 times higher when it is 15 to 29. Interpretation is unreliable below an eGFR of 15 [2].
What is a normal C-peptide level?
There is no single standard. Published fasting lower limits range from 0.165 to 0.364 nmol/L and upper limits from 0.596 to 1.5 nmol/L, and assay systems can differ by up to 36% [5]. The reference range printed on the lab report is the one to use.

References

  1. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013;30(7):803-17. The clinical utility of C-peptide measurement in the care of patients with diabetes
  2. Vinay ES, Laxmi Narsimha Rao B, Saf N, Gautam D. C-peptide in Precision Diabetes Care and Beyond: A Comprehensive Review. Clin Med Insights Endocrinol Diabetes. 2026;19:11795514251397811. C-peptide in Precision Diabetes Care and Beyond: A Comprehensive Review
  3. Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009;94(3):709-28. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline
  4. C-Peptide Test: MedlinePlus Medical Test. C-Peptide Test: MedlinePlus Medical Test
  5. Schleicher E, Kabytaev K, Nauck M, Müller-Wieland D, Peter A, Little RR, et al. Call for Standardization of C-Peptide Measurement. J Diabetes Sci Technol. 2025:19322968251362848. Call for Standardization of C-Peptide Measurement
  6. . Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med. 1998;128(7):517-23. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group
  7. Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251-260. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
  8. Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Evidence overview for C-Peptide Medication-Driven Changes: What Your Labs Mean and How Drugs Shift the Numbers